Sequencing and re-expressing B cell receptors from lymphoma tissue of rheumatoid arthritis patients reveals polyreactive and ...
A network meta-analysis of 15 randomized trials ranks telitacicept highest for SRI-4 response in lupus but links it to more ...
Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings. Povetacicept, a dual inhibitor of B-cell activating factor ...
Artiva Biotherapeutics Inc. ARTV announced it will halt further clinical development of its lead cell therapy candidate, ...
Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other ...
Mexico's health regulator authorized the country's first clinical trial using domestically manufactured CAR-T cells, allowing ...
The case study demonstrates a durable complete response in a heavily pretreated DLBCL patient after a single administration ...
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial; Updated deep B cell depletion and clinical response data is consistent with ...
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated ...
Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results